⌘+K

Pulse Explore Communities Researchers Journals

Browser extensionInstagram

Home Communities Explore

January 1, 2026Cancer Treatment and Research CommunicationsOpen Access

Treatment and outcomes of patients with HR+/HER2− early breast cancer in a real-world setting in Germany

Klaus-Ulrich Däßler Volker Petersen Mark-Oliver Zahn Walid Fakhouri Agnieszka Korfel Anna Emde Tatjana Rößler L. Kruggel Susanne Tech Martina Jänicke Katja Gratzke

View Full Paper

Ask AI

Bookmark

Share

Key Points

Patients with HR+/HER2- early breast cancer frequently exhibit high-risk characteristics that negatively affect prognosis.
A significant proportion of HR+/HER2- patients present with adverse clinicopathological features, necessitating improved treatments.
Observational analysis illustrates the urgent need for new treatment strategies in managing this specific patient population.
Findings suggest that tailored interventions may be crucial to address the challenges faced by high-risk HR+/HER2- breast cancer patients.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Ask your own question…

Implication

Observational analysis highlights the need for novel treatment strategies in high-risk HR+/HER2- early breast cancer patients.

Abstract

No abstract yet. The journal hasn't published one we can show.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Däßler et al. (2026) studied this question.

synapsesocial.com/papers/69a75f3ac6e9836116a2a74d https://doi.org/10.1016/j.ctarc.2026.101122

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 10 related papers. Consider them for comparative context:

1Breast cancer recurrence: factors impacting occurrence and survivalPrognostic Study · 2022 · 86 citations
2Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries2021 · 119,779 citations
3US Incidence of Breast Cancer Subtypes Defined by Joint Hormone Receptor and HER2 StatusRegistry Study · 2014 · 1,599 citations
4Impact of Breast Cancer Subtypes on Prognosis of Women with Operable Invasive Breast Cancer: A Population-based Study Using SEER DatabaseCohort Study · 2018 · 186 citations
5Hazard of Recurrence among Women after Primary Breast Cancer Treatment—A 10-Year Follow-up Using Data from SEER-MedicareCohort Study · 2012 · 137 citations
6Annual Hazard Rates of Recurrence for Breast Cancer During 24 Years of Follow-Up: Results From the International Breast Cancer Study Group Trials I to VCohort Study · 2016 · 653 citations
7Reducing chemotherapy use in clinically high-risk, genomically low-risk pN0 and pN1 early breast cancer patients: five-year data from the prospective, randomised phase 3 West German Study Group (WSG) PlanB trialCohort Study · 2017 · 189 citations
8Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE)Late-Phase Clinical Trial · 2020 · 1,080 citations
9Proportion, Histopathological Spectrum, and Clinicopathological Characteristics of Soft Tissue Sarcomas in Cameroon: A Sixteen-Year Retrospective Registry-Based StudyCancer Treatment and Research Communications · 2026
10Assessment of Peripheral and Tumor Specific Tregs and Th17 cells in Patients with Endometrial CancerCancer Treatment and Research Communications · 2026

More from Cancer Treatment and Research Communications

More from Eli Lilly (United States)

More from Olgahospital

More from Eli Lilly (Germany)

More from Forschungszentrum Energiespeichertechnologien

More from Heidenhain (Germany)

More from Iomedico (Germany)